Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 20 2024
0mins
Source: Globenewswire
Event Announcement: The Life Sciences Virtual Investor Forum held on September 19, 2024, is now available for online viewing, featuring presentations from various companies in the life sciences sector.
Investor Engagement: The presentations will be accessible for 90 days, and select companies are open to one-on-one management meeting requests until September 24th.
Analyst Views on APRE
Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.842
Low
5.00
Averages
5.00
High
5.00
Current: 0.842
Low
5.00
Averages
5.00
High
5.00
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
